

Attorney Docket No. 3477-110

PATENT #
6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: O'Dowd et al.

Group Art Unit: 1653

Application No.: 10/509,787

Examiner: TBD

Filed: September 30, 2005

Confirmation No. 3131

For: METHOD OF IDENTIFYING TRANSMEMBRANE
PROTEIN-INTERACTING COMPOUNDS

Date: August 9, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Respectfully submitted,

Karen A. Magri
Registration No. 41,965

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

"Express Mail" mailing label number: EV674756120US

Date of Deposit: August 9, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Sarah Brunmeier

Customer No. 20792

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401

Substitute form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	16,009,787		
		Filing Date	September 30, 2004		
		First Named Inventor	O'Dowd et al.		
		Group Art Unit	1653		
		Examiner Name	TBA		
Sheet	A1	of	A2	Attorney Docket Number	3477-110

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
	1.		WO 97/48820		Aurora BioSciences Corp.	24 December 1997	
	2.		WO 99/05177		The Regents of the Univ. of California	4 February 1999	

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	3.	Bailey et al.; "Patent Status of the therapeutically important G-protein-coupled receptors", <i>Expert Opin. Ther. Patents</i> 11: 1861-1887 (2001).	
	4.	Barak et al.; "A β -Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation", <i>The Journal of Biological Chemistry</i> 272: 44 27497-27500 (1997).	
	5.	Bertin et al.; "Cellular signaling by an agonist-activated receptor/G α fusion protein", <i>Proc. Natl. Acad. Sci.</i> 91: 8827-8831 (1994).	
	6.	Chen et al.; "A functional angiotensin II receptor-GFP fusion protein: evidence for agonist-dependent nuclear translocation", <i>Am J Physical Renal Physiol</i> 279: F440-F448 (2000).	
	7.	Conway et al.; "Quantitative analysis of Agonist-dependent parathyroid hormone receptor trafficking in whole cells using a functional green fluorescent protein conjugate", <i>J of Cellular Physiol</i> 189: 341-355 (2001).	
	8.	Coward et al.; "Chimeric G proteins allow a high-throughput signaling assay of G $_i$ -Coupled receptors" <i>Analytical Biochemistry</i> 270: 242-248 (1999).	
	9.	George et al.; "Oligomerization of μ and δ -Opioid receptors", <i>J of Biological Chemistry</i> 275:34 26128-26135 (2000).	
	10.	George et al.; "G-protein-coupled receptor oligomerization and its potential for drug discovery", <i>Nature</i> 1: 808-820 (2002).	
	11.	Görlich et al.; "Nucleocytoplasmic transport", <i>Science</i> 271: 1513-1518 (1996).	
	12.	Grötzinger; "Molecular mechanisms of cytokine receptor activation", <i>Biochimica et Biophysica Acta</i> 1592: 215-223 (2002).	
	13.	Hailey et al.; "Fluorescence resonance energy transfer using color variants of green fluorescent protein", <i>Methods in Enzymology</i> 351: 34-49 (2002).	
	14.	Hanahan et al.; "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis", <i>Cell</i> 86: 353-364 (1996).	
	15.	Howard et al.; "Orphan G-protein-coupled receptors and natural ligand discovery", <i>Trends in Pharmacological Sciences</i> 22:3 132-140 (2001).	
	16.	Howell et al.; "Live-cell nucleocytoplasmic protein shuttle assay utilizing laser confocal microscopy and FRAP", <i>BioTechniques</i> 32: 80-87 (2002).	
	17.	Jans et al.; "Nuclear targeting signal recognition: a key control point in nuclear transport?", <i>BioEssays</i> 22: 532-544 (2000).	
	18.	Lee et al.; "Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets", <i>Expert Opin. Ther. Targets</i> 6: 2 185-202 (2002).	
	19.	Lee et al.; "Oligomerization of dopamine and serotonin receptors", <i>Neuropsychopharmacology</i> 23: S32-S40 (2000).	
	20.	Lu et al.; "Angiotensin II-Induced nuclear targeting of the Angiotensin Type 1 (AT $_1$) receptor in brain neurons", <i>Endocrinology</i> 139:1 365-375 (1998).	
	21.	Masson et al.; "Neurotransmitter transporters in the central nervous system", <i>Pharmacological Reviews</i> 51:3 439-464 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/309,787	
			Filing Date	September 30, 2004	
			First Named Inventor	O'Dowd et al.	
			Group Art Unit	1653	
			Examiner Name	TBA	
Sheet	A2	of	A2	Attorney Docket Number	3477-110

22.	Matz et al.; "Fluorescent proteins from nonbioluminescent anthozoa species", <i>Nature Biotechnology</i> 17: 969-973 (1999).	
23.	Nakae et al.; "Distinct and overlapping functions of insulin and IGF-I receptors", <i>Endocrine Reviews</i> 22: 6 818-835 (2001).	
24.	Nicholson et al.; "EGFR and cancer prognosis", <i>European Journal of Cancer</i> 37: S9-S15 (2001).	
25.	O'Dowd et al.; "Short Communication: Discovery of three novel G-protein-coupled receptor genes", <i>Genomics</i> 47: 310-313 (1997).	
26.	Prasher et al.; "Primary structure of the Aequorea Victoria green-fluorescent protein", <i>Gene</i> 111: 229-233 (1992).	
27.	Schlenstedt; "Protein import into the nucleus", <i>Fed. Of Europ. Biochem. Soc.</i> 389: 75-79 (1996).	
28.	Shawver et al.; "Smart drugs: tyrosine kinase inhibitors in cancer therapy", <i>Cancer Cell</i> 1: 117-123 (2002).	
29.	Smith; "Screening for drug discovery: the leading question", <i>Nature</i> 418: 452-459 (2002).	
30.	Strickland et al.; "Diverse roles for the LDL receptor family", <i>Trends in Endocrinology & Metabolism</i> 13: 2 (66-73).	
31.	Watson et al.; "Nuclear localization of the type 1 parathyroid hormone/parathyroid hormone-related peptide receptor in MC3T3-E1 cells: association with serum0induced cell proliferation", <i>Bone</i> 26:3 221-225 (2000).	
32.	Weis; "Importins and exportins: how to get in and out of the nucleus", <i>TIBS</i> 23: 185-189 (1998).	
33.	White et al.; "Heterodimerization is required for the formation of a functional GABA _B receptor" <i>Nature</i> 396: 679-682 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.